Study: sales rep limits reduce off-label prescriptions

Study: sales rep limits reduce off-label prescriptions


Researchers found that limiting sales rep access and interactions reduces off-label prescriptions for the previously detailed drugs, while also upping off-label prescriptions of the drugs that had not been promoted.

FDA boots Wellbutrin generic

The agency says the copycat antidepressant failed to meet bioequivalency requirements.

Business briefs: Mayo Clinic, GSK, Lundbeck, Biogen Idec

Mayo Clinic says 70% of adults are on an Rx, with 25% of older women on an anti-depressant; GSK sinks $24M into rare-disease venture fund; Lundbeck restructures, and may kill 50 jobs; and Tecfidera is reportedly on-track for blockbuster sales estimates but still faces reimbursement hurdles.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters